NCT03204812View on ClinicalTrials.gov

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneProstate AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
BIOLOGICAL

Durvalumab

Given IV

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03204812 - Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter